HIS Research Group

The Humoral Immunology Section studies the antibody response to HIV-1 and SARS-COV-2 infection or vaccination. Ongoing research focuses on antibody discovery and antibody-virus co-evolution in infected patients or non-human primate models, with the goals of providing templates for vaccine design and antibodies with potential for clinical utility in preventing or treating infection.

Richard Koup, M.D.

Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory and Immunology Section
Acting Chief, Humoral Immunology Section

Contact: For contact information, search the NIH Enterprise Directory.


M.D., 1982, Johns Hopkins University School of Medicine, Baltimore, MD

M.S., 1979, University of Connecticut​, Stamford, CT

B.S., 1978, University of Connecticut​, Stamford, CT

Dr. Koup received his B.S. in biophysics in 1978 and his M.S. in biochemistry in 1979 from the University of Connecticut​. He attended Johns Hopkins University School of Medicine, where he obtained his M.D. in 1982. Dr. Koup served an internship and residency in internal medicine with the Rhode Island Hospital, Brown University Medical School, Providence, Rhode Island, from 1982 to 1985.

Learn more about Richard Koup, M.D.

Richard Koup, M.D.

Nicole Doria-Rose, Ph.D. (She/Her/Hers)

Chief, Humoral Immunology Core
Vaccine Research Center

Contact: For contact information, search the NIH Enterprise Directory.


Ph.D., 1998, Cornell University, Ithaca, NY

Nicole Doria-Rose, PhD is Chief of the Humoral Immunology Core at the Vaccine Research Center, National Institutes of Health, USA. She obtained her PhD from Cornell University in 1998 followed by post-doctoral work at the Seattle Biomedical Research Institute. Her research focus is the identification and characterization of broadly neutralizing antibodies from HIV-infected patients, with an emphasis on patients followed from the time of infection. She developed a high-throughput method for culturing and screening single B cells for antibody discovery, and with this method her team isolated the most potently HIV-neutralizing antibody yet known. At the Vaccine Research Center, she leads a program that evaluates the immune responses to HIV-1 infection and to novel immunogens, and investigates the clinical use of broadly neutralizing antibodies for prevention of HIV-1. She also led a team to develop a neutralization assay for SARS-CoV-2, the virus that causes COVID-19, and provided data in support of the mRNA vaccines now in use worldwide.

Learn more about Nicole Doria-Rose, Ph.D.

Nicole Doria-Rose, Ph.D.

Former Research Group Members

Xueling Wu, Ph.D. - Currently faculty at the Aaron Diamond AIDS Research Center at Columbia University. 

Rebecca Lynch, Ph.D. - Currently faculty at George Washington University 

Rui Kong, Ph.D. - Currently faculty at Emory University 

Content last reviewed on